Brief review: management of lupus nephritis–randomized controlled trials: an update

Shih-Han S. Huang, Ainslie Hildebrand, William F. Clark

.

DOI: 10.4236/ojim.2011.12006                

Abstract

Lupus nephritis leads to significant morbidity and mortality in patients with systemic lupus erythematous. Immunosuppressive agents are recommended in management of Class III, IV and V lupus nephritis. The goals of therapy are to control the disease and to prevent relapse while minimizing side-effects of therapy. Most of the evidences in managements of Class III and IV lupus nephritis comes from randomized controlled trials using intravenous cyclophosphamides, oral mycophenolate mofetil and oral azathioprine. In Class V lupus nephritis, there are few studies available and they have assessed the use of intravenous cyclophsophamide, oral mycophenolates mofetil and oral cyclosporine. In this review article, we have summarized the major randomized controlled trials in managements of Class III, IV and V lupus nephritis and offer an interpretation of the evidence to date.

Keywords

Lupus Nephritis; Immunosppressive Therapy; Randomized Controlled Trials; Lupus Treatment update; Induction Therapy; Maintenance Therapy; Evidence Based Comparison

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Weening, J.J., D’Agati, V.D., Schwartz, M.M., Seshan, S.V., Alpers, C.E., Appel, G.B., Balow, J.E., Bruijn, J.A., Cook, T., Ferrario, F., Fogo, A.B., Ginzler, E.M., Hebert, L., Hill, G., Hill, P., Jennette, J.C., Kong, N.C., Lesavre, P., Lockshin, M., Looi, L.M., Makino, H., Moura, L.A. and Nagata, M. (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology, 15, 241-250. doi:10.1097/01.ASN.0000108969.21691.5D
[2]	Illei, G.G., Austin, H.A., Crane, M., Collins, L., Gourley, M.F., Yarboro, C.H., Vaughan, E.M., Kuroiwa, T., Danning, C.L., Steinberg, A.D., Klippel, J.H., Balow, J.E. and Boumpas, D.T. (2001) Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Annals of Internal Medicine, 135, 248-257.
[3]	Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., Garrido Ed, E.R., Danieli, M.G., Abramovicz, D., Blockmans, D., Mathieu, A., Direskeneli, H., Galeazzi, M., et al. (2002) Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis & Rheumatism, 46, 2121-2131. doi:10.1002/art.10461
[4]	Houssiau, F.A., Vasconcelos, C., D’Cruz, D., Sebastiani, G.D., de Ramon, G.E., Danieli, M.G., Abramovicz, D., Blockmans, D., Cauli, A., Direskeneli, H., Galeazzi, M., Gul, A., Levy, Y., Petera, P., Popovic, R., Petrovic, R., Sinico, R.A., Cattaneo, R., Font, J., Depresseux, G., Cosyns, J.P. and Cervera, R. (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Annals of the Rheumatic Diseases, 69, 61-64. doi:10.1136/ard.2008.1025
[5]	Chan, T.M., Tse, K.C., Tang, C.S., Mok, M.Y. and Li, F.K. (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. Journal of the American Society of Nephrology , 16, 1076-1084. doi:10.1681/ASN.2004080686
[6]	Ong, L.M., Hooi, L.S., Lim, T.O., Goh, B.L., Ahmad, G., Ghazalli, R., Teo, S.M., Wong, H.S., Tan, S.Y., Shaariah, W., Tan, C.C. and Morad, Z. (2005) Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology, 10, 504-510. doi:10.1111/j.1440-1797.2005.00444.x
[7]	Ginzler, E.M., Dooley, M.A., Aranow, C., Kim, M.Y., Buyon, J., Merrill, J.T., Petri, M., Gilkeson, G.S., Wallace, D.J., Weisman, M.H. and Appel, G.B. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. The New England Journal of Medicine, 353, 2219-2228. doi:10.1056/NEJMoa043731
[8]	Appel, G.B., Contreras, G., Dooley, M.A., Ginzler, E.M., Isenberg, D., Jayne, D., Li, L.S., Mysler, E., Sanchez-Guerrero, J., Solomons, N. and Wofsy, D. (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. Journal of the American Society of Nephrology , 20, 1103-1112. doi:10.1681/ASN.2008101028
[9]	Contreras, G., Pardo, V., Leclercq, B., Lenz, O., Tozman, E., O’Nan, P. and Roth, D. (2004) Sequential therapies for proliferative lupus nephritis. The New England Journal of Medicine, 350, 971-980. doi:10.1056/NEJMoa031855
[10]	Miyasaka, N., Kawai, S. and Hashimoto, H. (2009) Efficacy and safety of tacrolimus for lupus nephritis: A placebo-controlled double-blind multicenter study. Modern Rheumatology, 19, 606-615. doi:10.1007/s10165-009-0218-5
[11]	Chen, W., Tang, X., Liu, Q., Chen, W., Fu, P., Liu, F., Liao, Y., Yang, Z., Zhang, J., Chen, J., Lou, T., Fu, J., Kong, Y., Liu, Z., Fan, A., Rao, S., Li, Z. and Yu, X. (2011) Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. American Journal of Kidney Diseases, 57, 235-244. doi:10.1053/j.ajkd.2010.08.036
[12]	Lewis, E.J., Hunsicker, L.G., Lan, S.P., Rohde, R.D. and Lachin, J.M. (1992) A controlled trial of plasmapheresis therapy in severe lupus nephritis. New England Journal of Medicine, 326, 1373-1379. doi:10.1056/NEJM199205213262101
[13]	Melander, C., Sallee, M., Trolliet, P., Candon, S., Belenfant, X., Daugas, E., Remy, P., Zarrouk, V., Pillebout, E., Jacquot, C., Boffa, J.J., Karras, A., Masse, V., Lesavre, P., Elie, C., Brocheriou, I., Knebelmann, B., Noel, L.H. and Fakhouri, F. (2009) Rituximab in severe lupus nephritis: Early B-cell depletion affects long-term renal outcome. Clinical Journal of the American Society of Nephrology, 4, 579-587. doi:10.2215/CJN.04030808
[14]	Bosch, X. (2010) Inflammation: Rituximab in ANCA vasculitis and lupus: Bittersweet results. Nature Reviews Nephrology, 6, 137-139. doi:10.1038/nrneph.2010.13
[15]	Jayne, D., Passweg, J., Marmont, A., Farge, D., Zhao, X., Arnold, R., Hiepe, F., Lisukov, I., Musso, M., Ou-Yang, J., Marsh, J., Wulffraat, N., Besalduch, J., Bingham, S.J., Emery, P., Brune, M., Fassas, A., Faulkner, L., Ferster, A., Fiehn, C., Fouillard, L., Geromin, A., Greinix, H., Rabusin, M., Saccardi, R., Schneider, P., Zintl, F., Gratwohl, A. and Tyndall, A. (2004) Autologous stem cell transplantation for systemic lupus erythematosus. Lupus, 13, 168-176. doi:10.1191/0961203304lu525oa
[16]	Burt, R.K., Traynor, A., Statkute, L., Barr, W.G., Rosa, R., Schroeder, J., Verda, L., Krosnjar, N., Quigley, K., Yaung, K., Villa, B.M., Takahashi, M., Jovanovic, B., Oyama, Y. (2006) Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. Journal of the American Medical Association, 295, 527-535. doi:10.1001/jama.295.5.527
[17]	Korbet, S.M. (1999) Membranous lupus glomerulonephritis. Oxford University Press, Oxford, 219-240.
[18]	Austin III, H.A., Illei, G.G., Braun, M.J., Balow, J.E. (2009) Randomized, controlled trial of prednisone, cyclophosphamide, and cyclosporine in lupus membranous nephropathy. Journal of the American Society of Nephrology, 20, 901-911. doi:10.1681/ASN.2008060665
[19]	Radhakrishnan, J., Moutzouris, D.A., Ginzler, E.M., Solomons, N., Siempos, I.I. and Appel, G.B. (2010) Mycophenolate mofetil and intravenous cyclophosphamide are similar as induction therapy for class V lupus nephritis. Kidney International, 77, 152-160. doi:10.1038/ki.2009.412
[20]	Clark, W.F. and Sontrop, J.M. (2008) What have we learned about optimal induction therapy for lupus nephritis (III through V) from randomized, controlled trials? Clinical Journal of the American Society of Nephrology, 3, 895-898. doi:10.2215/CJN.00170108